MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why ONMD Stock dropped -2.02% Today — RQD Quant Desk Flash
$4.37 -2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.35
OneMedNet Corp (Class A) (ONMD) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $26.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.35 (-0.55%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ONMD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY ONMD SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (28% of score)
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 37.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.30+4.9% Next Q
21
Q2 (-2Q)Grade E$4.51+4.4% Next Q
24
Q3 (-1Q)Grade E$4.71-7.2% Next Q
26
CurrentGrade E$4.37-9.8% Hist 90D α
29
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ONMD Turnaround Squeeze
While ONMD currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.55) and Max Pain ($4.59) forces dealer call-delta covering toward $24.15.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ONMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ONMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ONMD Stock dropped -2.02% Today — RQD Quant Desk Flash
OneMedNet Corp (Class A) (ONMD) dropped -2.02% to $4.37, trading at 4% of its 52-week range ($3.61 – $23). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($3.61 – $23) with RSI-14 at 37.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.37 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live ONMD Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ONMD)
- ✓Walkthrough of ONMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ONMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -59.54%▼ DESCENDING CHANNEL
2026-10-30O $4.21H $4.37L $4.10C $4.37VOL 61.0K
RES: $7.45SUP: $2.71SMA50: $5.55SMA200: $7.20
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ONMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +111.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ONMD today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ONMD. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ONMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ONMD)
Health Care Rank #960 of 1016
⚔️ BIAF vs ONMD Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ONMD vs. BIAF, MXCT, ISPC, NRC)
Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, OneMedNet Corp (Class A) (ONMD) ranks #960 by composite RQD confidence (29/100, grade E) and #818 by equity capitalization ($26.3M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with ONMD at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ONMD
ACTIVE
OneMedNet Corp (Class A) | E | 29/100 | — | -30.0% | -35.0% | -2.02% | $26.3M | Benchmark Subject |
| BIAF bioAffinity Technologies Inc. | E | 32/100 | — | — | -35.0% | -3.50% | $3.9M | /biaf-vs-onmd → |
| MXCT MaxCyte Inc. | E | 30/100 | — | 96.0% | -27.1% | +1.17% | $178.5M | /mxct-vs-onmd → |
| ISPC iSpecimen Inc. | D- | 39/100 | — | 11.2% | -35.0% | -9.35% | $2.0M | /ispc-vs-onmd → |
| NRC NRC Health | C | 65/100 | 44.8x | — | 21.0% | +0.09% | $519.6M | /nrc-vs-onmd → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001849380In its most recent audited fiscal period (FY2025, filed 2025-12-31), OneMedNet Corp (Class A) (ONMD) reported GAAP revenue of $1.4M (+111.4% vs. FY2024 revenue of $643.0K , and +33.1% cumulative change since FY2023) , GAAP net income of -$2.8M, operating cash flow of -$7.5M, and free cash flow of -$7.5M (-7.3% YoY). On the balance sheet, ONMD closed FY2025 with $2.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.4M | -$2.8M | -$7.5M | -$7.5M | $2.2M | — |
| FY2024 (FY) | 2024-12-31 | $643.0K | -$10.1M | -$7.0M | -$7.0M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $1.0M | -$33.8M | -$4.8M | -$4.8M | — | — |
3. ONMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ONMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, OneMedNet Corp (Class A) (NASDAQ: ONMD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.37 (-2.02% 1D, market cap $26.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ONMD ranks #960 in composite RQD confidence.
How does ONMD compare to BIAF and MXCT in the Health Care sector?
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), ONMD carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, BIAF (bioAffinity Technologies Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.9M) and MXCT (MaxCyte Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -27.1%, cap $178.5M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ONMD?
Per ONMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001849380), OneMedNet Corp (Class A) generated $1.4M in revenue (+111.4% YoY), -$2.8M in net income, and -$7.5M in free cash flow against $2.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ONMD trading relative to its 50-day, 200-day, and 52-week technical levels?
ONMD last traded at $4.37 (-2.02% on volume of 47,964 shares), positioning the stock -21.26% below its 50-day simple moving average ($5.55) and -39.31% below its 200-day simple moving average ($7.20). Across its 52-week range of $3.61 to $23.00, ONMD sits at the 3.9% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.82 to $4.92).
ONMD Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ONMD stock moving today?
Why ONMD Stock dropped -2.02% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.